Source: Elanco
Elanco Animal Health announced full USDA approval of its Canine Parvovirus Monoclonal Antibody (CPMA), now branded as Trutect™, the first and only approved treatment for deadly canine parvovirus. Initially conditionally approved in May 2023, the treatment has already helped save thousands of puppies nationwide. Real-world data show a 93% survival rate among treated puppies, shorter hospital stays by nearly two days, and high satisfaction among veterinarians.
In June 2025, the USDA also approved Trutect for passive immunity, allowing it to be used preventively in exposed puppies, with studies showing 100% effectiveness in preventing infection when given prophylactically. Parvo affects more than 330,000 puppies annually and can be fatal without care. Elanco has expanded access through donations to clinics and shelters, investments in manufacturing, national awareness efforts, and a $200 rebate for pet owners, reinforcing its mission to defend puppies and defeat parvo.
Read the full story HERE: https://www.elanco.com/us/newsroom/press-releases/trutect-USDA-approval